{
    "clinical_study": {
        "@rank": "161486", 
        "arm_group": {
            "arm_group_label": "Icotinib", 
            "arm_group_type": "Experimental", 
            "description": "Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period  takes about 24 months"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of dose escalation of\n      Icotinib in advanced non small cell lung cancer (NSCLC) patients after the therapy of\n      Icotinib, Iressa and Tarceva."
        }, 
        "brief_title": "Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "NSCLC", 
        "detailed_description": {
            "textblock": "-  1:to evaluate the efficacy correlation between the tyrosine kinase inhibitor (TKI)\n           drugs and high-dose Icotonib group in advanced NSCLC patients with high -dose Icotinib\n           going on after the routine TKI therapy\n\n        -  2 to evaluate the efficacy correlation between different high-dose group in advanced\n           NSCLC patients with high -dose Icotinib going on after the routine TKI therapy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. NSCLC patients were confirmed by histology or cytology\n\n          2. The time interval must be over 4 weeks from previous chemotherapy to registration to\n             participate in this experiment if he or she received chemotherapy,and also have any\n             toxicity to recover.\n\n          3. at least one measureable lesion accord to RECIST 1.1 criteria and the lesion accepted\n             no radiotherapy.\n\n               -  1 at least one measureable lesion .if only one measureable lesion, the\n                  biological nature must be confirmed by cytology or histology.\n\n               -  2 a single diameter of lesion could be measured by at least one of the following\n                  methods: Chest or abdominal computed tomography(CT)or magnetic resonance\n                  imaging(MRI),conventional methods of diameter at least 20mm diameter spiral CT\n                  OR at least 10mm.\n\n          4. ECOG 0-2 score\n\n          5. at least 12 weeks of expected survival time\n\n          6. Women of childbearing age must have a pregnancy test 7 days before treatment and the\n             result were negative ,men of childbearing age: surgical sterilization or treatment\n             during and after the end of three months to take contraceptive measures\n\n          7. understand and sign a written informed consent voluntarily.\n\n        Exclusion Criteria:\n\n        If  the subject meet any of the following exclusion criteria ,he is no eligible to\n        participate in this study,\n\n          1. Before enrollment in this trial have used Erbitux, Herceptin and carried out\n             anti-cancer therapy.\n\n          2. use of phenytoin, carbamazepine, rifampicin, phenobarbital or St. John's Wort when\n             take this trial\n\n          3. severe allergies to Icotinib"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963195", 
            "org_study_id": "DEI-ADNSCLC"
        }, 
        "intervention": {
            "arm_group_label": "Icotinib", 
            "description": "Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period  takes about 24 months", 
            "intervention_name": "Icotinib", 
            "intervention_type": "Drug", 
            "other_name": "high dose of Icotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Adverse Reaction to Drug", 
            "Self Efficacy"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "contact": {
                "email": "drliuhu@gmail.com", 
                "last_name": "Hu Liu, MD", 
                "phone": "865512922987"
            }, 
            "facility": {
                "address": {
                    "city": "Hefei", 
                    "country": "China", 
                    "state": "Anhui", 
                    "zip": "230032"
                }, 
                "name": "Dept. of Oncology,The First Affiliated Hospital of Anhui Medical Univesrsity"
            }, 
            "investigator": {
                "last_name": "Yueyin Pan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open, Single Center Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After TKI Therapy", 
        "overall_contact": {
            "email": "drliuhu@gmail.com", 
            "last_name": "Hu Liu, MD", 
            "phone": "865512922987"
        }, 
        "overall_official": {
            "affiliation": "Anhui Medical University", 
            "last_name": "Yueyin Pan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The efficacy of dose escalation of Icotinib in advanced NSCLC patients after failure of TKI (Icotinib  125mg po tid. Iressa 250mg po qd. Tarceva 150mg po qd) therapy will be evaluated according to the revised RECIST 1.1 (Response Evaluation Criteria In Solid Tumors).\nThe safety of high dosage of Icotinib will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.", 
            "measure": "safety and efficacy", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963195"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Anhui Medical University", 
            "investigator_full_name": "Pan Yueyin", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Anhui Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anhui Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}